Skip to main content
Fig. 1 | Molecular Neurodegeneration

Fig. 1

From: Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology

Fig. 1

Distribution of immunoassay and mass spectrometry p-tau181, p-tau217 and p-tau231 concentrations by clinical diagnosis. Density plots represent the proportion of subjects (y-axis) at different concentrations of p-tau (x-axis) for mass spectrometry-based quantification of p-tau (top row & 3rd row) and immunoassay-based quantification of p-tau (2.nd row & bottom row). P-tau217 showed high specificity for AD with lower values for young adults and CU older adults. CUY = Cognitively unimpaired young adults; CU = Cognitively unimpaired older adults; MCI = Mild cognitive impairment; AD = Alzheimer’s disease; OND = Other neurodegenerative disease. *: p < 0.05; ** p < 0.01; *** p < 0.005; **** p < 0.001

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326